Triple therapy shows promise for stage IV breast cancer

NCT ID NCT02778685

First seen Feb 28, 2026 · Last updated May 13, 2026 · Updated 6 times

Summary

This study tested whether adding an immunotherapy drug (pembrolizumab) to standard hormone therapy (letrozole) and a targeted drug (palbociclib) could shrink tumors in postmenopausal women with newly diagnosed stage IV estrogen receptor-positive breast cancer. The 47 participants received the combination to see how many had a partial or complete response. The goal is to improve treatment options for advanced breast cancer that has spread.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Antelope Valley

    Lancaster, California, 93534, United States

  • City of Hope Corona

    Corona, California, 92879, United States

  • City of Hope Medical Center

    Duarte, California, 91010, United States

  • City of Hope Mission Hills

    Mission Hills, California, 91345, United States

  • City of Hope South Pasadena

    South Pasadena, California, 91030, United States

  • City of Hope Upland

    Upland, California, 91786, United States

  • City of Hope West Covina

    West Covina, California, 91790, United States

Conditions

Explore the condition pages connected to this study.